Press release
AL Amyloidosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millenni
"AL Amyloidosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the AL Amyloidosis Market.
The AL Amyloidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the AL Amyloidosis Pipeline Report: https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel AL Amyloidosis treatment therapies with a considerable amount of success over the years.
• AL Amyloidosis companies working in the treatment market are HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others, are developing therapies for the AL Amyloidosis treatment
• Emerging AL Amyloidosis therapies in the different phases of clinical trials are- LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others are expected to have a significant impact on the AL Amyloidosis market in the coming years.
• In September 2023, The FDA has granted orphan drug designation to the next-generation BCMA-directed CAR T-cell therapy NXC-201 (formerly HBI0101) for treating patients with amyloid light chain (AL) amyloidosis.
• In May 2023, Nexcella reported promising early-stage cell therapy results in light chain (AL) amyloidosis. The company presented new Phase Ib/IIa (NCT04720313) data for its chimeric antigen receptor T (CAR-T) therapy NXC-201 at the Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.
• In February 2022, To assess the effectiveness of Isatuximab Plus Pomalidomide and Dexamethasone (IPd) in patients with AL Amyloidosis who were not in VGPR or improved after any prior therapy, Sanofi started a Phase II, open label, multicenter, single-stage research.
AL Amyloidosis Overview
The most prevalent kind of systemic amyloidosis, AL Amyloidosis, is connected to a plasma cell dyscrasia. A condition affecting the bone marrow results in amyloidosis. The bone marrow in the middle of bones creates "plasma cells," which are blood system cells.
Get a Free Sample PDF Report to know more about AL Amyloidosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging AL Amyloidosis Drugs Under Different Phases of Clinical Development Include:
• LambdaMab: HaemaLogiX
• ZN d5: Zentalis Pharmaceuticals
• STI-6129: Sorrento Therapeutics
• Isatuximab: Sanofi
• Bendamustine: Astellas Pharma GmbH
• Belantamab mafodotin: GlaxoSmithKline
• Ixazomib: Takeda Oncology
• CAEL-101: Caelum Biosciences
AL Amyloidosis Route of Administration
AL Amyloidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
AL Amyloidosis Molecule Type
AL Amyloidosis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
AL Amyloidosis Pipeline Therapeutics Assessment
• AL Amyloidosis Assessment by Product Type
• AL Amyloidosis By Stage and Product Type
• AL Amyloidosis Assessment by Route of Administration
• AL Amyloidosis By Stage and Route of Administration
• AL Amyloidosis Assessment by Molecule Type
• AL Amyloidosis by Stage and Molecule Type
DelveInsight's AL Amyloidosis Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further AL Amyloidosis product details are provided in the report. Download the AL Amyloidosis pipeline report to learn more about the emerging AL Amyloidosis therapies at:
https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the AL Amyloidosis Therapeutics Market include:
Key companies developing therapies for AL Amyloidosis are - Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and others.
AL Amyloidosis Pipeline Analysis:
The AL Amyloidosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of AL Amyloidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AL Amyloidosis Treatment.
• AL Amyloidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• AL Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the AL Amyloidosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about AL Amyloidosis drugs and therapies:
https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
AL Amyloidosis Pipeline Market Drivers
• Increase in the number of patients suffering from AL Amyloidosis, increase in awareness about the disease are some of the important factors that are fueling the AL Amyloidosis Market.
AL Amyloidosis Pipeline Market Barriers
• However, high cost of the associated treatment, side effects associated with the treatment and other factors are creating obstacles in the AL Amyloidosis Market growth.
Scope of AL Amyloidosis Pipeline Drug Insight
• Coverage: Global
• Key AL Amyloidosis Companies: HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others
• Key AL Amyloidosis Therapies: LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others
• AL Amyloidosis Therapeutic Assessment: AL Amyloidosis current marketed and AL Amyloidosis emerging therapies
• AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and AL Amyloidosis market barriers
Request for Sample PDF Report for AL Amyloidosis Pipeline Assessment and clinical trials:
https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. AL Amyloidosis Report Introduction
2. AL Amyloidosis Executive Summary
3. AL Amyloidosis Overview
4. AL Amyloidosis- Analytical Perspective In-depth Commercial Assessment
5. AL Amyloidosis Pipeline Therapeutics
6. AL Amyloidosis Late Stage Products (Phase II/III)
7. AL Amyloidosis Mid Stage Products (Phase II)
8. AL Amyloidosis Early Stage Products (Phase I)
9. AL Amyloidosis Preclinical Stage Products
10. AL Amyloidosis Therapeutics Assessment
11. AL Amyloidosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. AL Amyloidosis Key Companies
14. AL Amyloidosis Key Products
15. AL Amyloidosis Unmet Needs
16 . AL Amyloidosis Market Drivers and Barriers
17. AL Amyloidosis Future Perspectives and Conclusion
18. AL Amyloidosis Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports:
Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AL Amyloidosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millenni here
News-ID: 3500144 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Amyloidosis
Amyloidosis Market Massive Growth opportunity Ahead
Introduction
Amyloidosis is a rare, progressive disease characterized by the abnormal deposition of amyloid proteins in tissues and organs, leading to organ dysfunction and, in severe cases, life-threatening complications. The condition can affect the kidneys, heart, liver, and nervous system, making early detection and effective treatment essential. Historically underdiagnosed, amyloidosis is now gaining visibility due to advances in diagnostic tools, imaging technologies, and therapeutic innovations.
In 2024, the global Amyloidosis Market is…
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period?
The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at…
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market?
The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress…
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research..
The transthyretin amyloidosis treatment market size is…
AL Amyloidosis Therapeutics Market - Transforming the landscape of AL amyloidosi …
Newark, New Castle, USA: The "AL Amyloidosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
AL Amyloidosis Therapeutics Market: https://www.growthplusreports.com/report/al-amyloidosis-therapeutics-market/8684
This latest report researches the industry structure,…
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals…
